Professor Taylor is the clinical lead for ophthalmic research at the Royal Surrey County Hospital and was the Clinical Director for Research and Development at the Trust from 2014 to 2017. He was appointed to the position of Professor of Ophthalmology at the University of Surrey in 2015.

He runs an extensive clinical and laboratory research programme which was recognised with a career development fellowship from the UK National Institute of Health Research in 2011. His current research falls into several main areas:

• Retinal vein occlusion & diabetic eye disease (Clinical Trials, Publications)
• Macular degeneration (Clinical Trials, Publications)
• Uveitis, vasculitis and ocular inflammation (Clinical Trials, Publications)
• Cataract and vitrectomy surgery (Publications)

Clinical trials

Professor Taylor has been a principal investigator on over twenty clinical trials aimed at providing his patients with access to the latest treatments and improving outcomes in ophthalmic disease. His research has led to the adoption of new biological therapies into ophthalmic management, including the anti-B-cell therapy rituximab, as well as novel intraocular therapies such as methotrexate in uveitis.

Clinical trials currently running at the Royal Surrey are listed here.

He has presented the results of international multicentre clinical trials at international meetings and has been the recipient of over £1m in research funding.

Laboratory research

Professor Taylor's laboratory research is currently centred at the University of Surrey, where he is involved in the development of new therapeutic targets for retinal disease.

Publications

Professor Taylor has published over 100 peer-reviewed publications.

Professor Taylor is also on the editorial board of the British Journal of Hospital Medicine, BMC Ophthalmology, PLoS One, the Open Ophthalmology Journal and Case Reports in Ophthalmology. He has reviewed papers for more than 20 journals over the last five years, including ophthalmology, science and general medical journals.